title: First-line therapy in ovarian cancer trials.
abstract: At the 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG) held in Vancouver, Canada, in June 2010, representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. The process focused on 13 predetermined questions. Group A, 1 of the 3 discussion groups, addressed the first 5 questions, examining first-line therapies in newly diagnosed ovarian cancer patients. A1: What are the appropriate end points for different trials (maintenance, upfront chemotherapy trials including molecular drugs)? A2: Are there any subgroups defined by tumor biology who need specific treatment options/trials? A3: Is the 2004 GCIG-recommended standard comparator arm still valid? A4: What is the role of modifying dose, schedule, and delivery of chemotherapy? A5: What role does surgery play today?
authors.affiliation: GOG, Germany. jtthigpen@att.net
authors.forename: Tate
authors.initials: T
authors.lastname: Thigpen
authors.forename: Andreas
authors.initials: A
authors.lastname: duBois
authors.forename: Jessica
authors.initials: J
authors.lastname: McAlpine
authors.forename: Philip
authors.initials: P
authors.lastname: DiSaia
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.forename: William
authors.initials: W
authors.lastname: Hoskins
authors.forename: Gunnar
authors.initials: G
authors.lastname: Kristensen
authors.forename: Robert
authors.initials: R
authors.lastname: Mannel
authors.forename: Maurie
authors.initials: M
authors.lastname: Markman
authors.forename: Jacobus
authors.initials: J
authors.lastname: Pfisterer
authors.forename: Michael
authors.initials: M
authors.lastname: Quinn
authors.forename: Nick
authors.initials: N
authors.lastname: Reed
authors.forename: Ann Marie
authors.initials: AM
authors.lastname: Swart
authors.forename: Jonathan
authors.initials: J
authors.lastname: Berek
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Colombo
authors.forename: Gilles
authors.initials: G
authors.lastname: Freyer
authors.forename: Dolores
authors.initials: D
authors.lastname: Gallardo
authors.forename: Marie
authors.initials: M
authors.lastname: Plante
authors.forename: Andres
authors.initials: A
authors.lastname: Poveda
authors.forename: Lawrence
authors.initials: L
authors.lastname: Rubinstein
authors.forename: Monica
authors.initials: M
authors.lastname: Bacon
authors.forename: Henry
authors.initials: H
authors.lastname: Kitchener
authors.forename: Gavin C E
authors.initials: GC
authors.lastname: Stuart
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000379:methods*; D032921:Consensus; D023381:Endpoint Determination / Q000379:methods; D005260:Female; D013509:Gynecologic Surgical Procedures / Q000379:methods / Q000592:standards; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D020360:Neoadjuvant Therapy / Q000379:methods*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis